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Introduction
Bartonella bacilliformis is a pathogen that is endemic 
in some areas of the Andean region of Peru, southern 
Ecuador and southern Colombia. This pathogen causes 
so-called Carrion's disease, a biphasic disease with acute 
and chronic phases (called Oroya fever and "Peruvian 
wart" respectively1-3). In the absence or delay of 
antibiotic treatment, the mortality rate in the acute phase 
is up to 88%1. The acute phase is characterised by fever 
and severe anaemia and may be followed, several weeks 
or months later, by the chronic eruptive phase due to 
endothelial cell proliferation2. No animal reservoir has 
been identified to date and it is considered that healthy 
carriers act as a pathogen reservoir in endemic areas4.
B. bacilliformis is transmitted by sand-fly bites 
by members of the Lutzomyia genus3, although other 
mechanisms have been proposed such as mother-to-child 
vertical transmission5, or transfer through contaminated 
blood during transfusions or accidental contact2. Several 
Bartonella spp., including B. bacilliformis, are able 
to survive in blood stored for long periods of time6,7. 
Moreover, in animal studies, infections have been 
induced by Bartonella spp.-infected blood8. Thus, it is 
known that there is a risk of transmitting members of 
the Bartonella genus by transfusion.
Case report
A 47-year old male attended the outpatient clinic 
of the Hospital of Cajamarca, northern Peru, with 
anaemia, headache and dyspnoea, which had evolved 
over approximately 3 months. The patient had been 
diagnosed 2 years previously with chronic myeloid 
leukaemia and had been treated with imatinib 400 
mg/day for the first year, after which the patient 
discontinued treatment.
Physical examination revealed pallor and 
splenomegaly, but not jaundice. Blood analysis showed 
a haematocrit of 10%, a haemoglobin of 3.3 g/dL, white 
blood cell count of 5.0×104/mm3 and a platelet count 
of 3.4×104/mm3; additionally bone marrow analysis 
showed the presence of myeloid blasts (18%) and 
basophils (21%), all findings compatible with chronic 
myeloid leukaemia in accelerated phase. The patient 
received several packs of red blood cells (RBC) and 
platelet transfusion, and the imatinib treatment was 
restarted (600 mg/day). The patient was eventually 
discharged with a haemoglobin of 11.6 g/dL, total 
bilirubin of 0.8 mg/dL, and conjugated bilirubin of 
0.4 mg/dL. He was periodically controlled during the 
subsequent months and given various RBC and platelet 
transfusions (Figure 1).
On day 117 after his first visit, the patient attended 
the Emergency Department again, presenting with 
anaemia, fever (38.8 ºC), acute bloody diarrhoea, 
pallor, jaundice and splenomegaly, being treated with 
ceftriaxone (2 g/day) and additional RBC and platelet 
transfusions. 
Five days later (day 122), he developed additional 
anasarca and dyspnoea as well as pulmonary crackles, 
alanine transaminase and aspartate transaminase 
levels of 8 U/mL and 15 U/mL respectively and 
hyperbilirubinemia (total bilirubin: 6 mg/dL; conjugated 
bilirubin: 4.6 mg/dL) which suggested the need to 
withdraw the imatinib treatment. The anaemia appeared 
to be haemolytic in nature considering the refractoriness 
to blood transfusions and the concomitant rise in bilirubin 
levels. Therefore, a direct Coombs test was carried out 
(which was negative), a thin blood film was examined, 
polymerase chain reaction analysis (PCR) was performed 
and blood was cultured for B. bacilliformis9. The PCR 
results (data not shown) confirmed the presence of B. 
bacilliformis, and the patient was then diagnosed with 
Oroya fever. The antibiotic treatment was changed to 
parenteral ceftazidime (2 g/8 h) plus ciprofloxacin (200 
mg/12 h)10,11. The patient was discharged on day 136 
after being referred to a reference hospital for further 
chemotherapy of the chronic myeloid leukemia 
(Table I, Figure 1).
Concomitantly, a collaborative study between the 
Peruvian University of Applied Sciences (UPC) in 
Lima and the Hospital of Cajamarca was underway to 
determine the prevalence of bacterial pathogens not 
included in routine blood bank determinations, such 
as B. bacilliformis, amongst blood donors12,13. Within 
this study, after obtaining informed consent, 3 mL of 
whole blood were taken from blood donations prior to 
these being processed to obtain any blood component or 
derivative. In all cases, blood samples were stored at 4 ºC 
All rights reserved - For personal use only 
No other use without premission
© 
SIM
TI
 Se
rvi
zi 
Srl
2
Pons MJ et al
Blood Transfus DOI 10.2450/2015.0036-15
Table I - Clinical data during the patient's admission for Oroya fever.
Date 
(dd/mm/yyyy)
Day1 WBC 
(×mm3)
RBC
(×106)
Ht Hb Plt 
(×mm3)
Indirect bilirubin 
(mg/dL)
Total bilirubin 
(mg/dL)
Coombs2
07/05/2014 117 8,600 1.4 14 - 12,000 - - -
09/05/2014 119 8,100 2.6 22 - 10,000 3.3 - -
11/05/2014 121 - - 14 - - - - -
12/05/2014 122 4,200 1.3 12 4.0 - 4.6 6.0 Negative
13/05/2014 123 - - 10 3.9 7,000 - - -
14/05/2014 124 - - - 5,3 - - - -
16/05/2014 126 - - 20 6.5 5,000 - - -
17/05/2014 127 3,400 2.5 22 7.3 10,000 - - -
18/05/2014 128 - - 24 7.8 15,000 4.7 - -
20/05/2014 130 - - 32 10.7 5,000 4.7 9.0 -
21/05/2014 131 - - - 9.8 8,000 - - -
22/05/2014 132 - - - 10.7 - 4.0 6.7 -
23/05/2014 133 - - 30 9.8 10,000 - - -
25/05/2014 135 - - 27 9.0 5,000 2.1 3.5 -
26/05/2014 136 1,800 3.1 27 - 15,000 - - -
1Day after admission; 2Direct Coombs' test; WBC: white blood cells; RBC: red blood cells; Ht: haematocrit; Hb: haemoglobin; Plt: platelets.
Figure 1 - The patient's clinical course.
 No units are presented in the Y axis; the units corresponding to each parameter are indicated in the legend.
 Arrows indicate the contaminated transfusion, the admission due to Oroya fever and the subsequent discharge.
 The markers in the lines indicate the days on which the specific parameter was measured.
 RBC: red blood cells (packs transfused); PU: platelets units transfused; Hb: haemoglobin levels; BI: indirect bilirubin; BT: total 
bilirubin; Plt: platelets; CTX: cefotaxime; CAZ: ceftazidime; CIP: ciprofloxacin.
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B. bacilliformis in a blood donor
for a maximum of 1 week in the Hospital of Cajamarca 
prior to being sent to UPC. 
This study revealed the presence of B. bacilliformis 
in a blood donation from which platelets were obtained. 
These platelets were transfused to the above described 
patient 21 days prior (day 96) to admission to hospital 
with symptoms of Oroya fever. 
Discussion
Although blood transfusion is considered to be one of 
the mechanisms of transmitting B. bacilliformis, to the 
best of our knowledge such transmission has only been 
described once14. In 1972 it was reported that a neonate 
died of Oroya fever after a blood transfusion from a 
family member living in an area in which B. bacilliformis 
was endemic. Although vertical transmission has 
been proposed5, the mother did not have a previous 
Bartonella infection14. With regards to transfusion-
related transmission of other Bartonella spp., it was 
suspected that B. henselae had been transmitted by 
transfusion, but the fact was not firmly established15. 
Similarly, Scolfaro et al.16 reported possible transmission 
of B. henselae by a transplant, although natural infection 
could not be ruled out. 
Although B. bacilliformis infects RBC, the presence 
of this bacterium in a platelet concentrate is not 
surprising, because of the presence of bacteria outside 
of erythrocytes, and because the risk of transmitting 
bacterial infections by platelet concentrate transfusion is 
higher than that associated with the transfusion of RBC 
or other blood components. Indeed, platelet transfusions 
account for 87% of all blood transfusion-related bacterial 
infections17. 
In the present case, possible natural infection by a 
sand-fly bite cannot be ruled out, as the patient lived 
close to endemic areas. Although to the best of our 
knowledge the patient had not travelled out of Cajamarca 
city and thus had not been exposed to endemic areas, we 
want to be cautious on this point and consider that the 
patient may not have mentioned possible short journeys 
to nearby areas when interviewed. However, the facts 
that a platelet transfusion was contaminated with this 
microorganism and that the time elapsed from the 
transfusion to the emergency room visit was compatible 
with the incubation time11 strongly suggest transfusion-
related transmission.
Prior to the contaminated transfusion, the patient 
had marked decreases in platelet count (day 40 
onwards) and haemoglobin concentration (between 
days 80 [5.3 g/dL] and 94 [3.3 g/dL]). Although these 
facts might support a natural B. bacilliformis infection 
established before the contaminated platelet transfusion, 
the general health status of the patient must be taken 
into account in addition to the fact that alterations in 
RBC count (and thus in haemoglobin) and/or platelet 
count are common in the accelerated phase of chronic 
myeloid leukaemia. Additionally, the rise in bilirubin 
concentration occurred after the aforementioned 
transfusion, suggesting that the haemolytic anaemia may 
have arisen as a consequence of it.
Peruvian national legislation related to blood banks 
includes the obligation to screen for the presence of 
human immunodeficiency virus, human T-lymphotropic 
viruses 1 and 2, hepatitis B and C viruses, Trypanosoma 
cruzi and Treponema pallidum, while detection of other 
pathogens such as B. bacilliformis or Plasmodium spp. 
is only considered in Peruvian blood banks in endemic 
areas12,13. 
Carrion's disease is not distributed uniformly in 
the Cajamarca Department, being restricted to specific 
endemic areas, because of the Department's size (more 
than 35,000 km2) and great climatic diversities. The 
Hospital of Cajamarca is located in the capital of the 
Cajamarca Department, an urban area considered free 
of B. bacilliformis. Consequently routine screening in 
the hospital only tests for the seven pathogens specified 
in Peruvian national legislation12,13. Thus, in order to 
avoid transfusion risks, potential donors in the blood 
bank of the Hospital of Cajamarca are interviewed and 
those living in specific, endemic areas are not accepted 
as donors, because of the difficulties in making a correct 
diagnosis3,9. 
B. bacilliformis is a fastidious, slow-growing 
microorganism, requiring blood-enriched media, a 
temperature of 28-30 ºC, and 5% CO2 in order to 
grow9: bacterial cultures are not, therefore, useful for 
diagnosing B. bacilliformis infection, as in the present 
case, in which no positive cultures were obtained after 5 
months. In endemic areas techniques such as microscopy 
are often used; this has a diagnostic sensitivity ranging 
from 24 to 36% in patients with Oroya fever3, but has 
little utility in the case of asymptomatic carriers because 
of the low bacterial burden18. Molecular tools, such as 
PCR, which are often not available in endemic areas, 
provide better results but seem to have only limited value 
for detecting asymptomatic carriers9,19. There is a need 
for techniques with greater sensitivity, which could be 
used routinely in blood banks in endemic areas.
We found B. bacilliformis in a transfusion sample, 
thus demonstrating the potential risk of transfusion-related 
transmission, and highlighting the fact that a contaminated 
transfusion may be performed in a non-endemic area. This 
may be related to human travel, with inhabitants from 
endemic areas settling in non-endemic areas or inhabitants 
from non-endemic areas travelling to endemic ones. Such 
travel may facilitate the development of asymptomatic, 
B. bacilliformis carriers as blood donors and it should be 
taken into account that there are no data regarding the 
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duration of the status of a healthy carrier. In addition, 
due to the continuous movement of people and trade 
between the city and endemic areas, the introduction 
of vectors into the city of Cajamarca, a non-endemic 
area, cannot be excluded. This fact might result in the 
development of vector-borne diseases, as has been 
described in other areas20. 
In summary, the present report describes the presence 
of B. bacilliformis in a blood bank sample and the 
probable association between a blood transfusion and the 
development of Oroya fever, supporting the need for a 
sensitive detection technique that could be implemented 
in blood banks. 
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